BioVie director gets 90,000 & 330,500 options

BioVie Inc. director James Paul Lang reported new stock option awards.

Rhea-AI Filing Summary

BioVie Inc. director James Paul Lang reported new stock option awards. On January 5, 2026, he received two grants of stock options to buy BioVie common stock at an exercise price of $1.31 per share, one covering 90,000 shares and another covering 330,500 shares, both expiring on January 5, 2031.

The 90,000-share option vests in four equal installments on February 10, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of BioVie’s 2026 annual shareholders’ meeting. For the 330,500-share option, 75% vested on January 5, 2026, with the remaining portion vesting in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029. Both awards are held directly by the director and were reported as acquisitions of derivative securities.

Insider Trade Summary

Grant/Award: 420,500 shares

Grant/Award 2 txns

Insider Lang James Paul

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	90,000	$0.00	$0.00
Grant/Award	Stock Option (right to buy)	330,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 420,500 contracts (Direct)

Footnotes (2)

1. F1. The options vest in four equal installments on February 10, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting.
2. F2. 75% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioVie (BIVI) report for James Paul Lang?

The filing shows director James Paul Lang acquired two stock option grants on January 5, 2026, giving him the right to buy BioVie common stock at a fixed exercise price.

How many BioVie stock options were granted to director James Paul Lang?

He received one stock option covering 90,000 shares and another covering 330,500 shares of BioVie common stock, both reported as directly owned.

What is the exercise price and expiration date of James Paul Lang’s BioVie options?

Both stock option grants have an exercise price of $1.31 per share and an expiration date of January 5, 2031, according to the Form 4.

How do the 90,000 BioVie stock options granted to James Paul Lang vest?

The 90,000-share option vests in four equal installments on February 10, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of BioVie’s 2026 annual shareholders’ meeting.

What is the vesting schedule for the 330,500 BioVie options granted to James Paul Lang?

For the 330,500-share option, 75% vested on January 5, 2026; the remaining portion vests in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029.

Is James Paul Lang a director or officer of BioVie (BIVI) in this Form 4?

The Form 4 identifies James Paul Lang as a director of BioVie Inc. and not as an officer or 10% owner.

Are the reported BioVie stock options held directly or indirectly by James Paul Lang?

Both option positions are reported with ownership form Direct (D), indicating they are held directly by James Paul Lang rather than through another entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lang James Paul

(Last) (First) (Middle)

C/O BIOVIE INC.

680 W NYE LANE STE 201

(Street)

CARSON CITY NV 89703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOVIE INC. [ BIVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.31	01/05/2026		A		90,000		(1)	01/05/2031	Common Stock	90,000	$0.00	90,000	D
Stock Option (right to buy)	$1.31	01/05/2026		A		330,500		(2)	01/05/2031	Common Stock	330,500	$0.000	330,500	D

Explanation of Responses:

1. The options vest in four equal installments on February 10, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting.

2. 75% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029.

	/s/ Joanne Wendy Kim, attorney-in-fact for James Lang	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.